The Australian market has recently faced challenges, with the ASX200 dipping slightly and sectors like energy and financials underperforming due to falling commodity prices and economic concerns. In such a climate, investors often seek opportunities that balance potential growth with manageable risk, making penny stocks an intriguing option. Although considered a somewhat outdated term, penny stocks still represent affordable entry points into smaller or newer companies that may offer growth potential when backed by strong financial health.
Name
Share Price
Market Cap
Financial Health Rating
Embark Early Education (ASX:EVO)
A$0.785
A$144.03M
★★★★☆☆
LaserBond (ASX:LBL)
A$0.56
A$65.64M
★★★★★★
Helloworld Travel (ASX:HLO)
A$2.03
A$330.52M
★★★★★★
Austin Engineering (ASX:ANG)
A$0.52
A$322.48M
★★★★★☆
MaxiPARTS (ASX:MXI)
A$1.70
A$94.04M
★★★★★★
Navigator Global Investments (ASX:NGI)
A$1.595
A$781.68M
★★★★★☆
SHAPE Australia (ASX:SHA)
A$2.86
A$237.13M
★★★★★★
Vita Life Sciences (ASX:VLS)
A$2.04
A$114.72M
★★★★★★
Big River Industries (ASX:BRI)
A$1.32
A$112.7M
★★★★★☆
Servcorp (ASX:SRV)
A$4.90
A$483.46M
★★★★☆☆
Click here to see the full list of 1,046 stocks from our ASX Penny Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: ImpediMed Limited is a medical technology company that manufactures and sells bioimpedance spectroscopy (BIS) technology medical devices in the United States and Europe, with a market cap of A$109.27 million.
Operations: The company generates revenue from its medical segment, amounting to A$10.32 million.
Market Cap: A$109.27M
ImpediMed Limited, with a market cap of A$109.27 million, operates in the medical technology sector and generates revenue of A$10.32 million from its medical segment. The company is debt-free and has sufficient cash runway for over a year based on current free cash flow levels. Despite being unprofitable, ImpediMed has managed to reduce losses by 3.2% annually over the past five years and forecasts earnings growth of 67.52% per year. However, both its board and management team are relatively new, with average tenures of 1.3 years and 1 year respectively, which may impact strategic continuity.
ASX:IPD Financial Position Analysis as at Dec 2024
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Li-S Energy Limited focuses on developing and commercializing lithium sulphur and metal batteries in Australia, with a market capitalization of A$92.25 million.
Operations: Currently, there are no revenue segments reported for Li-S Energy Limited.
Market Cap: A$92.25M
Li-S Energy Limited, with a market cap of A$92.25 million, is pre-revenue and currently unprofitable. The company benefits from having no debt and sufficient cash runway for over a year based on its current free cash flow. Its short-term assets significantly exceed both short- and long-term liabilities, indicating strong liquidity. However, the stock has experienced high volatility recently, which may concern potential investors. The management team is relatively experienced with an average tenure of 2.8 years, but the board is newer with only 1.4 years average tenure per member. Recent board changes include electing Marc Fenton as a director in November 2024.
ASX:LIS Debt to Equity History and Analysis as at Dec 2024
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Straker Limited, along with its subsidiaries, provides language services and technology solutions across the Asia Pacific, Europe, the Middle East, Africa, and North America with a market cap of A$36.99 million.
Operations: The company generates NZ$47.23 million in revenue from its business services segment.
Market Cap: A$37M
Straker Limited, with a market cap of A$36.99 million, faces challenges as it reported a net loss of NZ$5.33 million for the half-year ending September 2024 and anticipates lower revenue in fiscal year 2025 due to contract non-renewals in Europe. Despite being unprofitable, Straker is debt-free and maintains a positive cash flow runway exceeding three years, supported by short-term assets covering liabilities comfortably. The management team is seasoned with an average tenure of nearly 12 years. However, the stock’s high volatility may present risks for investors considering exposure to this segment of the market.
ASX:STG Revenue & Expenses Breakdown as at Dec 2024
Jump into our full catalog of 1,046 ASX Penny Stocks here.
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:IPD ASX:LIS and ASX:STG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Bridget Roy is a news writer for Gibbs Press, where she covers sports, education, and tech. She's also a dedicated educator and advocate for children's rights. In her free time, Bridget likes to read, watch movies with her family, and play video games. She says that while she loves all of those things, they pale in comparison to her love of writing.
